Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a Buy rating on Evolent Health (EVH) but lowers the price target from $47 to $45.

February 23, 2024 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Evolent Health but lowers the price target from $47 to $45.
The adjustment in price target by Canaccord Genuity reflects a slight change in their valuation assessment of Evolent Health. While the reduction in price target could be perceived negatively, the maintenance of a Buy rating suggests that the analyst still sees positive potential in the stock. The impact on the stock price could be neutral to slightly negative in the short term as investors digest the implications of the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100